Cohance Lifesciences Ltd.

463-2.64%

2026-08-21

cohance.comBSE: 543064NSE: COHANCE
Market Cap₹ 17,125 Cr.
Current Price₹ 476
High / Low₹ 1,039 / 267
Stock P/E0.0
Book Value₹ 117
Price to Book12.85
Dividend Yield0.00 %
ROCE16.1 %
ROE12.6 %
Face Value₹ 1

Add ratio to table

ABOUT

KEY POINTS

PROS

  • Company is almost debt free
  • Promoters have been increasing their shareholding - up 7.4pp over 2 years
  • Company has a healthy return on capital (ROCE) of 23.9%
  • Strong cash generation - operating cash flow backs reported profits (CFO/PAT 1.17x)
  • Working capital cycle has improved - days down from 384 to 165
  • Company comfortably covers its interest (44.9x coverage)

CONS

  • Receivables are growing faster than sales - a possible quality concern
  • Recent results are weak - TTM profit is down 48.5% versus prior year
  • Total debt has risen sharply - up 81.4% year on year
  • Operating margins have contracted to 33.2% from 58.3%
  • Company has delivered a poor profit growth of 0.1% over past five years
  • Stock is trading at 12.8x its book value

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

EDIT COLUMNS
S.No.NameCMP Rs.P/EMar Cap Rs.Cr.Div Yld %NP Qtr Rs.Cr.Qtr Profit Var %Sales Qtr Rs.Cr.Qtr Sales Var %ROCE %OPM %
1.SUNPHARMA1898.0037.65455393.780.842901.2326.5315299.8810.9819.1128.81
2.DIVISLAB8525.0077.37226311.960.35902.0065.503080.0027.8021.5140.75
3.TORNTPHARM5013.0087.43190678.410.76566.003.284921.0057.3219.2733.81
4.CIPLA1416.0033.94114392.010.92785.55-39.187119.284.1316.0016.73
5.ZYDUSLIFE1105.0024.42110224.170.09990.20-34.908017.0023.9721.3924.54
6.LUPIN2220.0018.36101506.150.811416.9816.018276.8934.2828.8629.59
7.MANKIND2391.0048.3498747.340.04574.0929.124030.5912.8913.2426.30
8.DRREDDY1171.0030.3397740.540.68435.60-69.108099.80-5.2113.7510.63
9.LAURUSLABS1807.0089.3097634.420.11362.07123.942026.3129.1018.2031.50
10.AUROPHARMA1615.1525.0392932.160.251032.0325.229150.3517.4412.7620.54
11.BIOCON414.30136.3267518.230.12136.8053.364336.0010.893.2619.54
12.COHANCE447.60161.2117125.060.00-451.90-1073.924222.60668.7118.440.27
Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Jun 2023
344
173
Operating Profit
OPM %
Other Income
10
Interest
2
Depreciation
11
168
Tax %
25.86%
Net Profit
124
5
Equity Capital
25
Reserves
0
Promoter Pledge %
0.00%
Equity Capital
25
Reserves
0
Promoter Pledge %
0.00%
Sep 2023
225
127
Operating Profit
OPM %
Other Income
14
Interest
1
Depreciation
11
101
Tax %
25.69%
Net Profit
75
3
Equity Capital
25
Reserves
0
Promoter Pledge %
0.00%
Equity Capital
25
Reserves
0
Promoter Pledge %
0.00%
Dec 2023
213
144
Operating Profit
OPM %
Other Income
14
Interest
2
Depreciation
11
70
Tax %
24.66%
Net Profit
52
2
Equity Capital
25
Reserves
0
Promoter Pledge %
0.00%
Equity Capital
25
Reserves
0
Promoter Pledge %
0.00%
Mar 2024
253
180
Operating Profit
OPM %
Other Income
17
Interest
2
Depreciation
17
71
Tax %
24.87%
Net Profit
53
2
Equity Capital
25
Reserves
0
Promoter Pledge %
0.00%
Equity Capital
25
Reserves
0
Promoter Pledge %
0.00%
Jun 2024
488
363
Operating Profit
OPM %
Other Income
19
Interest
10
Depreciation
31
103
Tax %
26.82%
Net Profit
75
2
Equity Capital
25
Reserves
0
Promoter Pledge %
0.00%
Equity Capital
25
Reserves
0
Promoter Pledge %
0.00%
Sep 2024
594
391
Operating Profit
OPM %
Other Income
16
Interest
9
Depreciation
35
175
Tax %
20.65%
Net Profit
139
4
Equity Capital
25
Reserves
0
Promoter Pledge %
0.00%
Equity Capital
25
Reserves
0
Promoter Pledge %
0.00%
Dec 2024
653
421
Operating Profit
OPM %
Other Income
21
Interest
10
Depreciation
38
206
Tax %
25.33%
Net Profit
154
4
Equity Capital
25
Reserves
0
Promoter Pledge %
0.00%
Equity Capital
25
Reserves
0
Promoter Pledge %
0.00%
Mar 2025
769
546
Operating Profit
OPM %
Other Income
8
Interest
7
Depreciation
43
166
Tax %
25.86%
Net Profit
123
3
Equity Capital
25
Reserves
0
Promoter Pledge %
0.00%
Equity Capital
25
Reserves
0
Promoter Pledge %
0.00%
Jun 2025
484
379
Operating Profit
OPM %
Other Income
13
Interest
7
Depreciation
31
71
Tax %
26.00%
Net Profit
53
1
Equity Capital
38
Reserves
0
Promoter Pledge %
0.00%
Equity Capital
38
Reserves
0
Promoter Pledge %
0.00%
Sep 2025
498
367
Operating Profit
OPM %
Other Income
26
Interest
5
Depreciation
31
121
Tax %
21.89%
Net Profit
94
2
Equity Capital
38
Reserves
0
Promoter Pledge %
0.00%
Equity Capital
38
Reserves
0
Promoter Pledge %
0.00%
Dec 2025
482
379
Operating Profit
OPM %
Other Income
6
Interest
5
Depreciation
33
65
Tax %
27.72%
Net Profit
47
1
Equity Capital
38
Reserves
0
Promoter Pledge %
0.00%
Equity Capital
38
Reserves
0
Promoter Pledge %
0.00%
Mar 2026
568
451
Operating Profit
OPM %
Other Income
-1
Interest
5
Depreciation
38
56
Tax %
38.77%
Net Profit
35
1
Equity Capital
38
Reserves
0
Promoter Pledge %
0.00%
Equity Capital
38
Reserves
0
Promoter Pledge %
0.00%
Jun 2026
3,599
3,698
Operating Profit
OPM %
Other Income
122
Interest
21
Depreciation
343
22
Tax %
36.20%
Net Profit
14
0
Equity Capital
383
Reserves
0
Promoter Pledge %
0.00%
Equity Capital
383
Reserves
0
Promoter Pledge %
0.00%

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019
378
206
Operating Profit
172
OPM %
46
Other Income
1
Interest
3
Depreciation
11
158
Tax %
31
Net Profit
109
EPS
0
Dividend Payout %
Minority Interest
0
Share of Associates
0
Adjusted EPS
0
Minority Interest
0
Share of Associates
0
Adjusted EPS
0
Mar 2020
834
449
Operating Profit
403
OPM %
48
Other Income
18
Interest
22
Depreciation
24
358
Tax %
24
Net Profit
270
EPS
11
Dividend Payout %
24
Minority Interest
0
Share of Associates
0
Adjusted EPS
11
Minority Interest
0
Share of Associates
0
Adjusted EPS
11
Mar 2021
1,010
567
Operating Profit
457
OPM %
45
Other Income
14
Interest
12
Depreciation
32
414
Tax %
25
Net Profit
309
EPS
12
Dividend Payout %
16
Minority Interest
0
Share of Associates
0
Adjusted EPS
12
Minority Interest
0
Share of Associates
0
Adjusted EPS
12
Mar 2022
1,320
738
Operating Profit
770
OPM %
58
Other Income
188
Interest
9
Depreciation
39
722
Tax %
23
Net Profit
558
EPS
22
Dividend Payout %
23
Minority Interest
0
Share of Associates
0
Adjusted EPS
22
Minority Interest
0
Share of Associates
0
Adjusted EPS
22
Mar 2023
1,330
739
Operating Profit
635
OPM %
48
Other Income
45
Interest
13
Depreciation
43
579
Tax %
25
Net Profit
433
EPS
17
Dividend Payout %
35
Minority Interest
0
Share of Associates
0
Adjusted EPS
17
Minority Interest
0
Share of Associates
0
Adjusted EPS
17
Mar 2024
1,051
645
Operating Profit
462
OPM %
44
Other Income
57
Interest
7
Depreciation
55
400
Tax %
26
Net Profit
296
EPS
12
Dividend Payout %
0
Minority Interest
0
Share of Associates
0
Adjusted EPS
12
Minority Interest
0
Share of Associates
0
Adjusted EPS
12
Mar 2025
1,094
731
Operating Profit
417
OPM %
38
Other Income
54
Interest
8
Depreciation
57
351
Tax %
23
Net Profit
272
EPS
11
Dividend Payout %
0
Minority Interest
0
Share of Associates
0
Adjusted EPS
11
Minority Interest
0
Share of Associates
0
Adjusted EPS
11
TTM
1,907
1,567
Operating Profit
OPM %
Other Income
44
Interest
18
Depreciation
137
245
Tax %
27
Net Profit
178
EPS
Dividend Payout %
Minority Interest
0
Share of Associates
0
Adjusted EPS
Minority Interest
0
Share of Associates
0
Adjusted EPS

COMPOUNDED SALES GROWTH

10 Years:
5 Years:
6%
3 Years:
-6%

COMPOUNDED PROFIT GROWTH

10 Years:
5 Years:
0%
3 Years:
-21%

STOCK PRICE CAGR

10 Years:
5 Years:
3 Years:
1 Year:
-47%

RETURN ON EQUITY

10 Years:
5 Years:
26%
3 Years:
18%
Last Year:
13%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Corporate actions

2020

Sep 25

1:1

Employees Stock Option Plan & Bonus issue & Increase in Authorised Capital Inter alia, approved : 1. Issue of Bonus Shares The Board of Directors has considered, approved and recommended issue of (1:1) one Bonus Share for every one equity share held by the equity shareholders of the Company. The bonus issue of equity shares is subject to the approval of the shareholders in the ensuing annual general meeting and any other applicable statutory and regulatory approvals, as may be required. 2. The Second Annual General Meeting of the Company will be held on Monday the 14th day of September, 2020 at 11.30 a.m. IST. The Bonus shares once allotted shall rank pari-passu in all respects and carry the same rights of the existing Equity Shares and shall be entitled to participate in full in any dividend and other corporate action, recommended and declared, if any, after the issue and allotment of such Bonus Shares. 3. The Board of Directors has considered and approved increase in the Authorized Share Capital from Rs. 20.10 crores divided into 20.10 crores equity shares of Rs. 1/- each to Rs. 40.00 crores divided into 40.00 crores equity shares of Rs. 1/- each and consequential alteration in the Memorandum of Association of the Company, subject to the approval of shareholders of the Company. 4. The Board of Directors also approved granting of 10,00,000 (ten lakh only) Employee Stock options of Rs.1/- each under Suven Pharma Employee Stock Option Scheme 2020 (SPLESOP 2020) to the eligible employees of the Company and recommended to the members for their approval in the ensuing Annual General Meeting.

Mar 2019
Equity Capital
0
578
83
Trade Payables
54
102
Total Liabilities
816
271
Capital Work in Progress
111
7
157
0
Cash & Bank
13
257
Total Assets
816
Total Debt
83
Net Working Capital
232
Contingent Liabilities
11
Book Value per Share
0.00
Face Value
0.00
Total Debt
83
Net Working Capital
232
Contingent Liabilities
11
Book Value per Share
0.00
Face Value
0.00
Mar 2020
Equity Capital
13
770
94
Trade Payables
71
282
Total Liabilities
1,230
357
Capital Work in Progress
102
276
175
0
Cash & Bank
14
307
Total Assets
1,230
Total Debt
185
Net Working Capital
191
Contingent Liabilities
10
Book Value per Share
61.50
Face Value
1.00
Total Debt
185
Net Working Capital
191
Contingent Liabilities
10
Book Value per Share
61.50
Face Value
1.00
Mar 2021
Equity Capital
25
1,040
106
Trade Payables
83
207
Total Liabilities
1,461
441
Capital Work in Progress
96
426
201
0
Cash & Bank
10
286
Total Assets
1,461
Total Debt
141
Net Working Capital
345
Contingent Liabilities
6
Book Value per Share
41.84
Face Value
1.00
Total Debt
141
Net Working Capital
345
Contingent Liabilities
6
Book Value per Share
41.84
Face Value
1.00
Mar 2022
Equity Capital
25
1,495
67
Trade Payables
106
248
Total Liabilities
1,942
534
Capital Work in Progress
30
600
283
0
Cash & Bank
33
462
Total Assets
1,942
Total Debt
96
Net Working Capital
900
Contingent Liabilities
6
Book Value per Share
59.74
Face Value
1.00
Total Debt
96
Net Working Capital
900
Contingent Liabilities
6
Book Value per Share
59.74
Face Value
1.00
Mar 2023
Equity Capital
25
1,724
65
Trade Payables
67
222
Total Liabilities
2,103
512
Capital Work in Progress
165
710
311
0
Cash & Bank
46
358
Total Assets
2,103
Total Debt
69
Net Working Capital
801
Contingent Liabilities
6
Book Value per Share
68.72
Face Value
1.00
Total Debt
69
Net Working Capital
801
Contingent Liabilities
6
Book Value per Share
68.72
Face Value
1.00
Mar 2024
Equity Capital
25
2,001
39
Trade Payables
42
107
Total Liabilities
2,214
670
Capital Work in Progress
179
893
231
134
Cash & Bank
22
86
Total Assets
2,214
Total Debt
39
Net Working Capital
1,107
Contingent Liabilities
18
Book Value per Share
79.59
Face Value
1.00
Total Debt
39
Net Working Capital
1,107
Contingent Liabilities
18
Book Value per Share
79.59
Face Value
1.00
Mar 2025
Equity Capital
25
2,273
70
Trade Payables
71
148
Total Liabilities
2,588
685
Capital Work in Progress
253
1,116
154
242
Cash & Bank
23
114
Total Assets
2,588
Total Debt
70
Net Working Capital
495
Contingent Liabilities
19
Book Value per Share
90.29
Face Value
1.00
Total Debt
70
Net Working Capital
495
Contingent Liabilities
19
Book Value per Share
90.29
Face Value
1.00

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019
50
Cash from Investing
-65
Cash from Financing
26
11
Free Cash Flow
50
OCF / Net Profit
0.46
Cumulative 5-Year FCF
0
OCF / Net Profit
0.46
Cumulative 5-Year FCF
0
Mar 2020
359
Cash from Investing
-367
Cash from Financing
9
1
Free Cash Flow
259
OCF / Net Profit
1.33
Cumulative 5-Year FCF
0
OCF / Net Profit
1.33
Cumulative 5-Year FCF
0
Mar 2021
329
Cash from Investing
-258
Cash from Financing
-76
-4
Free Cash Flow
221
OCF / Net Profit
1.07
Cumulative 5-Year FCF
0
OCF / Net Profit
1.07
Cumulative 5-Year FCF
0
Mar 2022
270
Cash from Investing
-90
Cash from Financing
-156
23
Free Cash Flow
212
OCF / Net Profit
0.48
Cumulative 5-Year FCF
0
OCF / Net Profit
0.48
Cumulative 5-Year FCF
0
Mar 2023
493
Cash from Investing
-237
Cash from Financing
-243
13
Free Cash Flow
339
OCF / Net Profit
1.14
Cumulative 5-Year FCF
0
OCF / Net Profit
1.14
Cumulative 5-Year FCF
0
Mar 2024
376
Cash from Investing
-362
Cash from Financing
-40
-26
Free Cash Flow
146
OCF / Net Profit
1.27
Cumulative 5-Year FCF
1,177
OCF / Net Profit
1.27
Cumulative 5-Year FCF
1,177
Mar 2025
301
Cash from Investing
-321
Cash from Financing
21
1
Free Cash Flow
159
OCF / Net Profit
1.11
Cumulative 5-Year FCF
1,077
OCF / Net Profit
1.11
Cumulative 5-Year FCF
1,077

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019
EPS (₹)
0.00
Book Value (₹)
0.00
Dividend per Share (₹)
0.00
Cash EPS (₹)
0.00
Operating Margin %
45.56%
Net Margin %
28.92%
ROE %
18.92%
ROCE %
23.87%
13.39%
Debtor Days
142
Inventory Days
152
Payable Days
193
102
Debt to Equity (x)
0.14x
Interest Coverage (x)
57.60x
2.22x
Revenue Growth %
0.00%
Operating Profit Growth %
0.00%
Net Profit Growth %
0.00%
0.00%
P/E (x)
0.00x
P/B (x)
0.00x
Dividend Yield %
0.00%
0.00x
Mar 2020
EPS (₹)
21.22
Book Value (₹)
61.50
Dividend per Share (₹)
5.00
Cash EPS (₹)
11.53
Operating Margin %
48.32%
Net Margin %
32.39%
ROE %
39.71%
ROCE %
46.23%
26.40%
Debtor Days
58
Inventory Days
73
Payable Days
101
30
Debt to Equity (x)
0.24x
Interest Coverage (x)
17.39x
1.60x
Revenue Growth %
120.68%
Operating Profit Growth %
134.04%
Net Profit Growth %
147.16%
0.00%
P/E (x)
0.00x
P/B (x)
0.00x
Dividend Yield %
0.00%
0.00x
Mar 2021
EPS (₹)
12.12
Book Value (₹)
41.84
Dividend per Share (₹)
2.00
Cash EPS (₹)
13.37
Operating Margin %
45.29%
Net Margin %
30.57%
ROE %
33.40%
ROCE %
39.15%
22.94%
Debtor Days
40
Inventory Days
68
Payable Days
94
13
Debt to Equity (x)
0.13x
Interest Coverage (x)
36.49x
2.07x
Revenue Growth %
21.10%
Operating Profit Growth %
13.49%
Net Profit Growth %
14.28%
0.00%
P/E (x)
0.00x
P/B (x)
0.00x
Dividend Yield %
0.00%
0.00x
Mar 2022
EPS (₹)
21.92
Book Value (₹)
59.74
Dividend per Share (₹)
5.00
Cash EPS (₹)
23.46
Operating Margin %
58.29%
Net Margin %
42.24%
ROE %
43.17%
ROCE %
51.79%
32.80%
Debtor Days
47
Inventory Days
67
Payable Days
87
26
Debt to Equity (x)
0.06x
Interest Coverage (x)
85.72x
3.60x
Revenue Growth %
30.75%
Operating Profit Growth %
68.40%
Net Profit Growth %
80.82%
0.00%
P/E (x)
0.00x
P/B (x)
0.00x
Dividend Yield %
0.00%
0.00x
Mar 2023
EPS (₹)
16.99
Book Value (₹)
68.72
Dividend per Share (₹)
6.00
Cash EPS (₹)
18.69
Operating Margin %
47.72%
Net Margin %
32.50%
ROE %
26.46%
ROCE %
34.48%
21.39%
Debtor Days
47
Inventory Days
82
Payable Days
80
49
Debt to Equity (x)
0.04x
Interest Coverage (x)
46.45x
3.68x
Revenue Growth %
0.75%
Operating Profit Growth %
-17.51%
Net Profit Growth %
-22.49%
0.00%
P/E (x)
0.00x
P/B (x)
0.00x
Dividend Yield %
0.00%
0.00x
Mar 2024
EPS (₹)
11.64
Book Value (₹)
79.59
Dividend per Share (₹)
0.00
Cash EPS (₹)
13.79
Operating Margin %
38.60%
Net Margin %
28.20%
ROE %
15.70%
ROCE %
20.99%
13.74%
Debtor Days
42
Inventory Days
94
Payable Days
64
72
Debt to Equity (x)
0.02x
Interest Coverage (x)
54.75x
10.45x
Revenue Growth %
-20.96%
Operating Profit Growth %
-27.20%
Net Profit Growth %
-31.47%
-31.48%
P/E (x)
58.10x
P/B (x)
8.50x
Dividend Yield %
0.00%
37.28x
Mar 2025
EPS (₹)
10.67
Book Value (₹)
90.29
Dividend per Share (₹)
0.00
Cash EPS (₹)
12.92
Operating Margin %
33.16%
Net Margin %
24.85%
ROE %
12.56%
ROCE %
16.14%
11.32%
Debtor Days
63
Inventory Days
64
Payable Days
70
57
Debt to Equity (x)
0.03x
Interest Coverage (x)
44.92x
3.32x
Revenue Growth %
4.01%
Operating Profit Growth %
-9.93%
Net Profit Growth %
-8.35%
-8.35%
P/E (x)
108.68x
P/B (x)
12.85x
Dividend Yield %
0.00%
71.00x

Shareholding Pattern

Numbers in percentages

TRADES
Jun 2024
50.10
9.80
17.42
0.01
22.67
Sep 2024
50.10
10.70
16.95
0.01
22.25
Dec 2024
50.10
10.84
16.67
0.01
22.37
Mar 2025
50.10
11.05
16.60
0.01
22.23
Jun 2025
66.41
7.23
11.40
0.01
14.95
Sep 2025
57.49
6.51
20.81
0.01
15.17
Dec 2025
57.49
6.01
21.57
0.01
14.92
Mar 2026
57.49
5.59
21.79
0.01
15.12
Jun 2026
57.49
6.50
20.09
0.01
15.92

Documents

Announcements

Credit Ratings

  • Credit Rating- Others

    2026-08-13 - Cohance Lifesciences Limited has informed the Exchange about Credit Rating- Others

  • Credit Rating

    2025-12-03 - Cohance Lifesciences Limited has informed the Exchange about Credit Rating

  • Credit Rating

    2025-08-27 - Cohance Lifesciences Limited has informed the Exchange about Credit Rating

Concalls